Novel 5-aryloxypyrimidine SEN1576 as a candidate for the treatment of Alzheimer’s disease
International Journal of Neuropsychopharmacology Eugene O‘Hare, David I.C. Scopes, Eun-Mee Kim, Philip Palmer, David Spanswick, Bridgeen McMahon, Hozefa Amijee, Edmund Nerou, J. Mark Treherne and Ross Jeggo
International Journal of Neuropsychopharmacology
Eugene O‘Hare, David I.C. Scopes, Eun-Mee Kim, Philip Palmer, David Spanswick, Bridgeen McMahon, Hozefa Amijee, Edmund Nerou, J. Mark Treherne and Ross Jeggo
Prefibrillar assembly of amyloid-β (Aβ) is a major event underlying the development of neuropathology and dementia in Alzheimer’s disease (AD). This study determined the neuroprotective properties of an orally bioavailable Aβ synaptotoxicity inhibitor, SEN1576. Binding of SEN1576 to monomeric Aβ1–42 was measured using surface plasmon resonance. Thioflavin-T and MTT assays determined the ability of SEN1576 to block Aβ1–42-induced aggregation and reduction in cell viability, respectively. In vivo long-term potentiation (LTP) determined effects on synaptic toxicity induced by intracerebroventricular (i.c.v.) injection of cell-derived Aβ oligomers. An operant behavioural schedule measured effects of oral administration following i.c.v. injection of Aβ oligomers in normal rats. SEN1576 bound to monomeric Aβ1–42, protected neuronal cells exposed to Aβ1–42, reduced deficits in in vivo LTP and behaviour. SEN1576 exhibits the necessary features of a drug candidate for further development as a disease modifying treatment for the early stages of AD-like dementia.